- Browse by Author
Browsing by Author "Bledsoe, Joseph"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Clinical prediction rule for SARS-CoV-2 infection from 116 U.S. emergency departments 2-22-2021(PloS, 2021-03) Kline, Jeffrey A.; Camargo, Carlos A.; Courtney, D. Mark; Kabrhel, Christopher; Nordenholz, Kristen E.; Aufderheide, Thomas; Baugh, Joshua J.; Beiser, David G.; Bennett, Christopher L.; Bledsoe, Joseph; Castillo, Edward; Chisolm-Straker, Makini; Goldberg, Elizabeth M.; House, Hans; House, Stacey; Jang, Timothy; Lim, Stephen C.; Madsen, Troy E.; McCarthy, Danielle M.; Meltzer, Andrew; Moore, Stephen; Newgard, Craig; Pagenhardt, Justine; Pettit, Katherine L.; Pulia, Michael S.; Puskarich, Michael A.; Southerland, Lauren T.; Sparks, Scott; Turner-Lawrence, Danielle; Vrablik, Marie; Wang, Alfred; Weekes, Anthony J.; Westafer, Lauren; Wilburn, John; Emergency Medicine, School of MedicineObjectives Accurate and reliable criteria to rapidly estimate the probability of infection with the novel coronavirus-2 that causes the severe acute respiratory syndrome (SARS-CoV-2) and associated disease (COVID-19) remain an urgent unmet need, especially in emergency care. The objective was to derive and validate a clinical prediction score for SARS-CoV-2 infection that uses simple criteria widely available at the point of care. Methods Data came from the registry data from the national REgistry of suspected COVID-19 in EmeRgency care (RECOVER network) comprising 116 hospitals from 25 states in the US. Clinical variables and 30-day outcomes were abstracted from medical records of 19,850 emergency department (ED) patients tested for SARS-CoV-2. The criterion standard for diagnosis of SARS-CoV-2 required a positive molecular test from a swabbed sample or positive antibody testing within 30 days. The prediction score was derived from a 50% random sample (n = 9,925) using unadjusted analysis of 107 candidate variables as a screening step, followed by stepwise forward logistic regression on 72 variables. Results Multivariable regression yielded a 13-variable score, which was simplified to a 13-point score: +1 point each for age>50 years, measured temperature>37.5°C, oxygen saturation<95%, Black race, Hispanic or Latino ethnicity, household contact with known or suspected COVID-19, patient reported history of dry cough, anosmia/dysgeusia, myalgias or fever; and -1 point each for White race, no direct contact with infected person, or smoking. In the validation sample (n = 9,975), the probability from logistic regression score produced an area under the receiver operating characteristic curve of 0.80 (95% CI: 0.79–0.81), and this level of accuracy was retained across patients enrolled from the early spring to summer of 2020. In the simplified score, a score of zero produced a sensitivity of 95.6% (94.8–96.3%), specificity of 20.0% (19.0–21.0%), negative likelihood ratio of 0.22 (0.19–0.26). Increasing points on the simplified score predicted higher probability of infection (e.g., >75% probability with +5 or more points). Conclusion Criteria that are available at the point of care can accurately predict the probability of SARS-CoV-2 infection. These criteria could assist with decisions about isolation and testing at high throughput checkpoints.Item Study protocol for a multicentre implementation trial of monotherapy anticoagulation to expedite home treatment of patients diagnosed with venous thromboembolism in the emergency department(BMJ, 2020-10-01) Kline, Jeffrey A.; Adler, David; Alanis, Naomi; Bledsoe, Joseph; Courtney, Daniel; D'Etienne, James; Diercks, Deborah B.; Garrett, John; Jones, Alan E.; MacKenzie, David; Madsen, Troy; Matuskowitz, Andrew; Mumma, Bryn; Nordenholz, Kristen; Pagenhardt, Justine; Runyon, Michael; Stubblefield, William; Willoughby, Christopher; Emergency Medicine, School of MedicineIntroduction In the USA, many emergency departments (EDs) have established protocols to treat patients with newly diagnosed deep vein thrombosis (DVT) as outpatients. Similar treatment of patients with pulmonary embolism (PE) has been proposed, but no large-scale study has been published to evaluate a comprehensive, integrated protocol that employs monotherapy anticoagulation to treat patients diagnosed with DVT and PE in the ED. Methods and analysis This protocol describes the implementation of the Monotherapy Anticoagulation To expedite Home treatment of Venous ThromboEmbolism (MATH-VTE) study at 33 hospitals in the USA. The study was designed and executed to meet the requirements for the Standards for Reporting Implementation Studies guideline. The study was funded by investigator-initiated awards from industry, with Indiana University as the sponsor. The study principal investigator and study associates travelled to each site to provide on-site training. The protocol identically screens patients with both DVT or PE to determine low risk of death using either the modified Hestia criteria or physician judgement plus a negative result from the simplified PE severity index. Patients must be discharged from the ED within 24 hours of triage and treated with either apixaban or rivaroxaban. Overall effectiveness is based upon the primary efficacy and safety outcomes of recurrent VTE and bleeding requiring hospitalisation respectively. Target enrolment of 1300 patients was estimated with efficacy success defined as the upper limit of the 95% CI for the 30-day frequency of VTE recurrence below 2.0%. Thirty-three hospitals in 17 states were initiated in 2016–2017. Ethics and dissemination All sites had Institutional Review Board approval. We anticipate completion of enrolment in June 2020; study data will be available after peer-reviewed publication. MATH-VTE will provide information from a large multicentre sample of US patients about the efficacy and safety of home treatment of VTE with monotherapy anticoagulation.